Abstract
The present work describes a series of novel tetrahydroquinoline amines that potently inhibit the in vitro reuptake of serotonin and dopamine (dual reuptake inhibitors). The compounds are structurally related to a series we disclosed previously, but are improved with respect to cytochrome P-450 enzyme (CYP) and potassium ion channel Kv11.1 (hERG) inhibition and synthetic accessibility. The detailed synthesis and in vitro activity and ADME profile of the compounds is described, which represent a previously undisclosed dual reuptake inhibitor chemotype.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Dopamine Plasma Membrane Transport Proteins / antagonists & inhibitors*
-
Dopamine Plasma Membrane Transport Proteins / metabolism
-
Dopamine Uptake Inhibitors / chemical synthesis
-
Dopamine Uptake Inhibitors / chemistry*
-
Dopamine Uptake Inhibitors / pharmacokinetics
-
Drug Evaluation, Preclinical
-
Humans
-
Mice
-
Microsomes / metabolism
-
Quinolines / chemical synthesis
-
Quinolines / chemistry*
-
Quinolines / pharmacokinetics
-
Selective Serotonin Reuptake Inhibitors / chemical synthesis
-
Selective Serotonin Reuptake Inhibitors / chemistry*
-
Selective Serotonin Reuptake Inhibitors / pharmacokinetics
-
Serotonin Plasma Membrane Transport Proteins / chemistry*
-
Serotonin Plasma Membrane Transport Proteins / metabolism
Substances
-
1-(3,4-dichlorophenyl)-N,N-dimethyl-1,2,3,4-tetrahydroquinolin-4-amine
-
Dopamine Plasma Membrane Transport Proteins
-
Dopamine Uptake Inhibitors
-
Quinolines
-
Serotonin Plasma Membrane Transport Proteins
-
Serotonin Uptake Inhibitors